ConductScience.org, home

Paper41333366

Clinical outcomes of patients with advanced EGFR mutated nonsquamous cell lung carcinoma treated at a tertiary care hospital.

Ahmed F and 7 others. Ecancermedicalscience, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Clinical outcomes of patients with advanced EGFR mutated nonsquamous cell lung carcinoma treated at a tertiary care hospital. Papers, record 41333366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41333366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical outcomes of patients with advanced EGFR mutated nonsquamous cell lung carcinoma treated at a tertiary care hospital.
PubMed
Journal
Ecancermedicalscience
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-12-05
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ahmed FFaiza
2Amjad AAqsa
3Anwar EEman
4Naviwala MSSMohammad Saad Saleem
5Saleem WWarda
6Zehra NNawazish
7Moosajee MMunira
8Rashid YAYasmin Abdul

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137937763Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.N Engl J Med2023https://conductscience.org/library/papers/37937763PubMed
224663503Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?Cancer Chemother Pharmacol2014https://conductscience.org/library/papers/24663503PubMed
326579470Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Acta Pharm Sin B2015https://conductscience.org/library/papers/26579470PubMed
411784875Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med2002https://conductscience.org/library/papers/11784875PubMed
531751012Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med2020https://conductscience.org/library/papers/31751012PubMed
623594426Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.J Natl Cancer Inst2013https://conductscience.org/library/papers/23594426PubMed
731218108Survival and prognostic factors in non-small cell lung cancer patients with mutation of the EGFR gene treated with tyrosine kinase inhibitors in a peruvian hospital.Am J Cancer Res2019https://conductscience.org/library/papers/31218108PubMed
829371589Cell death-based treatment of lung adenocarcinoma.Cell Death Dis2018https://conductscience.org/library/papers/29371589PubMed
929079040Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population.Arch Bronconeumol (Engl Ed)2018https://conductscience.org/library/papers/29079040PubMed
1036817181
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study.
Lancet Reg Health Eur2023https://conductscience.org/library/papers/36817181PubMed
1134564820Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Target Oncol2021https://conductscience.org/library/papers/34564820PubMed
1223078958First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2012https://conductscience.org/library/papers/23078958PubMed
1319680293Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.Oncogene2009https://conductscience.org/library/papers/19680293PubMed
1433538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
1529496250Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.Lung Cancer2018https://conductscience.org/library/papers/29496250PubMed
1637279591Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Jpn J Clin Oncol2023https://conductscience.org/library/papers/37279591PubMed
1737196999Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study.J Cancer Allied Spec2023https://conductscience.org/library/papers/37196999PubMed
1831564718Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.Br J Cancer2019https://conductscience.org/library/papers/31564718PubMed
1918316005Small cell lung cancer.Mayo Clin Proc2008https://conductscience.org/library/papers/18316005PubMed
2030207593Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018https://conductscience.org/library/papers/30207593PubMed

See all 22 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41333366

GET https://conductscience.org/api/papers/v1/41333366/references?page=2